

The Lupus Research Alliance unites the global lupus community in bold determination to free the world of lupus through the power of science. We will transform the lives of people affected by lupus as we welcome and embrace a new scientific era; pioneer innovation; push the frontiers of knowledge; enlist diverse, new scientific talent; and lead the drive to new treatments, prevention, and a cure.

A YEAR OF PROGRESS:

CONTINUING TO ACCELERATE RESEARCH AND TREATMENTS

In 2022, the Lupus Research Alliance (LRA) invested \$18.3 million in novel lupus research, for a grand total of over \$245 million supporting more than 560 individual research awards since our founding in 1999. Importantly, that research has delivered priceless advances.

Last year, the U.S. Food and Drug Administration (FDA) approval of Benlysta as the first and only treatment for children whose lupus has attacked their kidneys was made possible in part by critical early research that we funded. Our support of pioneering research in CAR-T cell therapy led to the most dramatic clinical trial benefits yet: complete disease remission for up to two years among lupus patients who were not taking other therapies.

These two examples represent a fraction of our impact. Read on for highlights of the LRA's progress in 2022, pointing to what is possible ahead and offering even more hope for people living with lupus.

2022 ADVANCEMENTS AND HIGHLIGHTS

2022 was a year of remarkable success not only in advancing lupus research, but also in tackling fundamental issues that can personalize lupus care. This work has laid a foundation for several initiatives that will transform our understanding and treatment of lupus.

- The LRA's largest research investment, the **Global Team Science Award (GTSA)**, was given to three outstanding multidisciplinary teams from 14 institutions across four continents. Each team received \$3 million to pioneer research exploring why lupus differs from person to person, paving the way toward personalized treatments.
- Our clinical research affiliate, **Lupus Therapeutics**, collaborated with six biopharmaceutical companies on eight clinical trials, advancing much-needed potential new treatments.
- To help eradicate health disparities, which significantly hamper lupus research, the LRA launched several initiatives to improve diversity in research:
 - Inaugural **Diversity in Lupus Research Award**. Seven outstanding underrepresented minority researchers were given research grants totaling \$6.5 million, bringing diverse perspectives to the lupus field.
 - Results of our novel **Patient Advocates for Lupus Studies (PALS)** program showed that it effectively improved awareness and intention to participate in lupus clinical trials. Based on this success, we are expanding this program in 2023.
 - Our newest health equity initiative, **Project CHANGE**, aims to develop individual community-based programs that engage African Americans to participate in lupus clinical research.

Board of Directors

We extend our sincere gratitude to our Board of Directors, who fund all our administration and fundraising expenses. Their generosity allows us to commit 100% of other donations to support lupus research programs.

Ira Akselrad, Co-Chair
Richard K. DeScherer, Co-Chair
Brenda Blackmon, Secretary
Joseph Mauriello, Treasurer
Bishop Rudy V. Carlton
William "Willie" Colon
Thomas O. Daniel, M.D.
Jennie L. DeScherer
Katey Driscoll
Sir Marc Feldmann, AC, FRS
Moti Ferder
Anna R. Fisch
Joe Germanotta
David M. Kies
Daniel M. LaVecchia
Veronica Vargas Lupo
Molly McCabe
Nadeem Meghji
William J. Mulvihill
Robert Seder, M.D.
Daniel J. Wallace, M.D., F.A.C.P., M.A.C.R.
Julius Williams
William J. Wolfe
Spencer Zwick

Officers

Albert T. Roy, President & CEO
Stacie Bell, Ph.D., Executive Vice President, Lupus Therapeutics, LLC
Luke Easley, VP of HR and Administration
Penny Mitchell, VP of Marketing & Communications
Andrea J. O'Neill, VP & Chief Development Officer
Debra Rose, VP & Chief Financial Officer
Teodora Staeva, Ph.D., VP & Chief Scientific Officer

Scientific Advisory Board

Gary A. Koretzky, M.D., Ph.D., Chair
Laurent Araud, M.D., Ph.D.
Roberto Caricchio, M.D.
Andy Chan, M.D., Ph.D.
Mary Collins, Ph.D.
Nancy Gonzalez
Judith James, M.D., Ph.D.
Alfred Kim, M.D., Ph.D.
Josef Penninger, M.D.
David J. Rawlings, M.D.
Jason Williams



I'm with the Lupus Research Alliance because I hope that by educating and bringing awareness to what I go through – and what millions of others go through – that can lead to greater participation and funding of lupus research and, ultimately, one day a cure.

- Martin Lewis
LRA Young Leaders
Board Member



ENERGIZING A POWERFUL COMMUNITY

The lupus community remains at the center of everything we do, and its participation is paramount to our success. Our ManyOne Can Walk with Us to Cure Lupus program is a bold testament to the community's power. Every year, thousands of Walkers join our Walks to ensure better treatments and, ultimately, a cure. Last year alone, their passion generated nearly \$1.5 million for lupus research. Thousands more contributed greatly by participating in clinical research, advocating for more public funding for lupus research, and educating their communities about lupus. Thank you to all our donors and supporters for your invaluable help in our efforts to transform the lives of people with lupus.

EARNING EXCEPTIONAL RATINGS AS ONE OF THE MOST TRUSTED HEALTH ORGANIZATIONS

Once again, the LRA earned exceptional recognition as one of the best charities worldwide. We are proud to have earned four out of four stars by Charity Navigator, the Gold Seal of Transparency from Guidestar and a "Top Rated" status with an "A" ranking from nonprofit evaluator CharityWatch.

Following is an overview of the LRA's income and expenditures for the fiscal year ending December 31, 2022.

Revenue & Other Support:

Contributions	\$18,375,553
Other Support	\$ 2,874,122
Total Revenue & Other Support:	\$ 21,249,675

Program Expenditures:

Research	\$18,215,047
Scientific Programs	\$ 7,011,730
Public Policy	\$ 622,162
Total Program Expenditures:	\$ 25,849,939

Administration Expenditures: \$ 2,690,676*

Fundraising Expenditures: \$ 2,944,799*

End-of-Year Net Asset Balance: \$63,531,585


*The LRA's Supporting Services are covered by donations from its Board of Directors.

Total Liability & Net Assets: \$98,907,292

Total Assets: \$98,907,292

Quasi Endowments & Other Investments: \$86,853,912

Other Assets: \$12,053,380



The LRA contracts certified public accountants (CPAs) Lutz and Carr as its independent auditor. A complete copy of the audited financial statements of the LRA for the year ended December 31, 2022, together with the independent auditor's report thereon, may be obtained through a written request to the LRA's national office and is also available on the LRA website: lupusresearch.org. The LRA is tax exempt under 501(c)(3) of the Internal Revenue Code. Donations are tax deductible to the extent allowed by law.

270 Madison Avenue, Suite 300, New York, NY 10016